575,607 Shares in Drugs Made In America Acquisition II Corp. $DMII Purchased by Radcliffe Capital Management L.P.

Radcliffe Capital Management L.P. purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 575,607 shares of the company’s stock, valued at approximately $5,699,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. ABC Arbitrage SA bought a new position in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $396,000. Deltec Asset Management LLC acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $495,000. Royal Bank of Canada bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $655,000. Finally, PEAK6 LLC acquired a new stake in Drugs Made In America Acquisition II in the 4th quarter valued at about $990,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on DMII shares. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Drugs Made In America Acquisition II has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Up 0.0%

NASDAQ DMII opened at $10.09 on Wednesday. The business’s 50-day moving average is $10.04. Drugs Made In America Acquisition II Corp. has a 52-week low of $9.86 and a 52-week high of $10.09.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.